



## DAFTAR PUSTAKA

- Ahmad, S. & Mokaddas, E., 2014. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis. *J Infect Public Health*. [Online] 7(2):75–91. Available from: doi:10.1016/j.jiph.2013.09.001.
- Ahmad, A.M., Akhtar, S., Hasan, R., Khan, J.A., et al., 2012. Risk factors for multidrug-resistant tuberculosis in urban Pakistan: A multicenter case–control study. *Int J Mycobacteriol*. [Online] 1(3):137–142. Available from: doi:10.1016/j.ijmyco.2012.07.007.
- Ahuja, S.D., Ashkin, D., Avendano, M., Banerjee, R., et al., 2012. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: An individual patient data meta-analysis of 9,153 Patients. *PLoS Med*. [Online] 9(8):1-16. Available from: doi:10.1371/journal.pmed.1001300.
- Alene, K.A., Viney, K., McBryde, E.S., Tsegaye, A.T., et al., 2017. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia. *Trop Med Int Health*. [Online] 22(3):351–362. Available from: doi:10.1111/tmi.12826.
- Anonymous, 2014. *RSUD Labuang Baji Makassar*. [Online] [cited 2017 July 4]. Available from: <http://www.rsudlbsulsel.co.id/pages-2-sejarah>
- Anonymous, 2015. *Profil RSUD Dr. Moewardi*. Solo, RSUD Dr. Moewardi.
- Baghaei, P., Tabarsi, P., Dorriz, D., Marjani, M., et al., 2011. Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran. *Am J Ther*. [Online] 18(2):29-34. Available from: doi:10.1097/MJT.0b013e3181c0806d.
- Chen, M.-Y., Lo, Y.-C., Chen, W.-C., Wang, K.-F., et al., 2017. Recurrence after Successful Treatment of Multidrug-Resistant Tuberculosis in Taiwan. *PLOS ONE* [Online] 12(1):1-14. Available from: doi:10.1371/journal.pone.0170980.
- Chiang, C.-Y., Enarson, D.A., Yu, M.-C., Bai, K.-J., et al., 2006. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. *Eur Respir J*. [Online] 28(5):980–985. Available from: doi:10.1183/09031936.06.00125705.
- Deck, D.H., Winston, L.G., 2012. Antimycobacterial drugs. In: Katzung, B.G., Masters, S.B., Trevor, A.J.,(Ed.): *Basic & Clinical Pharmacology*, pp:839-848. McGraw Hill, New York.



- de Vries, G., Tsoлова, S., van der Werf, M.J., 2017. Health system factors influencing management of multidrug-resistant tuberculosis in four European Union countries - learning from country experiences. *BMC Public Health* 17:334.
- Dheda, K., Gumbo, T., Maartens, G., Dooley, K.E., et al., 2017. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. *Lancet Respir Med.* [Online] 5(4):291–360. Available from: doi:10.1016/S2213-2600(17)30079-6.
- Drlica, K., Zhao, X., 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. *Microbiol Mol Biol Rev* 61(3):377.
- Falzon, D., Gandhi, N., Migliori, G.B., Sotgiu, G., et al., 2013. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. *Eur Respir J.* [Online] 42(1):156–168. Available from: doi:10.1183/09031936.00134712.
- Farley, J.E., Ram, M., Pan, W., Waldman, S., et al., 2011. Outcomes of Multi-Drug Resistant Tuberculosis (MDR-TB) among a Cohort of South African Patients with High HIV Prevalence. *PLOS ONE* [Online] 6(7):1-7. Available from: doi:10.1371/journal.pone.0020436.
- Faustini, A., Hall, A.J. & Perucci, C.A., 2006. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. *Thorax* [Online] 61(2):158–163. Available from: doi:10.1136/thx.2005.045963.
- Gadallah, M.A., Mokhtar, A., Rady, M., El-Moghazy, E., et al., 2016. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt. *J Formos Med Assoc.* [Online] 115(11):997–1003. Available from: doi:10.1016/j.jfma.2015.10.002.
- Helbling, P., Altpeter, E., Egger, J.M., Zellweger, J.P., 2014. Treatment outcomes of multidrug-resistant tuberculosis in Switzerland. *Swiss Med Wkly.* 144:1-7.
- Hoa, N.B., Nhung, N.V., Khanh, P.H., Hai, N.V., et al., 2015. Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam. *BMC Res Notes.* [Online] 8:1-6. Available from: doi:10.1186/s13104-015-1806-4.
- Jain, K., Desai, M., Solanki, R. & Dikshit, R.K., 2014. Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis. *J*



- Pharmacol Pharmacother.* [Online] 5(2):145–149. Available from: doi:10.4103/0976-500X.130062.
- Janmeja, A.K., Aggarwal, D. & Dhillon, R., 2018. Factors predicting treatment success in multi-drug resistant tuberculosis patients treated under programmatic conditions. *Indian J Tuberc.* [Online] 65(2):135–139. Available from: doi:10.1016/j.ijtb.2017.12.015.
- Jiang, RH., Xu, HB., Li, L., 2013. Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study. *Int J Antimicrob Agents.* 42:36-41.
- Kemkes RI, 2014. *Pedoman nasional pengendalian tuberkulosis.* Kementerian Kesehatan RI, Jakarta.
- Keshavjee, S., Gelmanova, S., Shin, S.S., Mishutin, S.P., 2012. Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome. *Int J Tuberc Lung Dis* 16(5):596-603.
- Khaliukin, A., Kumar, A.M.V., Skrahina, A., Hurevich, H., 2014. Poor treatment outcomes among multidrug-resistant tuberculosis patients in Gomel Region, Republic of Belarus. *Pub Health Act* 4(3):24-28.
- Kibret, K.T., Moges, Y., Memiah, P. & Biadgilign, S., 2017. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies. *Infect Dis Poverty.* [Online] 6(7):1-8. Available from: doi:10.1186/s40249-016-0214-x.
- Krasniqi, S., Jakupi, A., Daci, A., Tigani, B., et al., 2017. Tuberculosis treatment adherence of patients in Kosovo. *Tuberc Res Treat.* [Online] 2017:1–8. Available from: doi:10.1155/2017/4850324.
- Leimane, V., Riekstina, V., Holtz, T.H., Zarovska, E., et al., 2005. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. *Lancet* [Online] 365(9456):318–326. Available from: doi:10.1016/S0140-6736(05)17786-1.
- Liu, Y.-X., Pang, C.-K., Liu, Y., Sun, X.-B., et al, 2015. Association between Multidrug-Resistant Tuberculosis and Risk Factors in China: Applying Partial Least Squares Path Modeling. *PLoS ONE* [Online] 10(5):1-13. Available from: doi:10.1371/journal.pone.0128298.
- Maldonado, H.J., Cruz, M., Nieves, J., Rivera, K., et al., 2016. New strain multidrug resistant tuberculosis G24767 in Puerto Rico: Old disease a continuous threat. *Respir Med Case Reports.* [Online] 19:86–88. Available from: doi:10.1016/j.rmcr.2016.08.001.



- Marra, F., Marra, C.A., Moadebi, S., Shi, P., Elwood, R.K., Stark, G., FitzGerald, J.M., 2005. Levofloxacin treatment of active tuberculosis and the risk of adverse events. *CHEST* 128:1406-1413.
- Munawwarah. R., Leida, I., Wahiduddin, 2013. Gambaran faktor risiko pengobatan pasien TB-MDR RS Labuang Baji Kota Makassar tahun 2013 [Online] [cited 2017 July 3]. Available from: <http://repository.unhas.ac.id/bitstream/handle/123456789/5530/JURNAL.pdf?sequence=1> [Accessed: 4 July 2017a].
- Nair, D., Velayutham, B., Kannan, T., Tripathy, J.P., et al., 2017. Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India. *Public Health Act.* [Online] 7(1):32–38. Available from: doi:10.5588/pha.16.0055.
- Nagpal, M., Devgun, P., Chawla, N., 2015. A study on nutritional status and change in body mass index with treatment outcome in smear-positive pulmonary TB patients on DOTS in Amritsar city. *Int J Med Sci Public Health* 4(4):454-457.
- Palomino, J.C. & Martin, A., 2014. Drug resistance mechanisms in *Mycobacterium tuberculosis*. *Antibiot.* [Online] 3(3):317–340. Available from: doi:10.3390/antibiotics3030317.
- Podewils, L.J., Gler, M.T.S., Quelapio, M.I. & Chen, M.P., 2013. Patterns of treatment interruption among patients with multidrug-resistant TB (MDR TB) and association with interim and final treatment outcomes. *PLOS ONE* [Online] 8(7):1-8. Available from: doi:10.1371/journal.pone.0070064.
- Prasad, R., Singh, A., Srivastava, R., Hosmane, G.B., et al. (2016) Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis. *Indian J Tuberc.* [Online] 63(2):106–114. Available from: doi:10.1016/j.ijtb.2016.01.031.
- Prosser, G, de Carvalho, L.P.S., 2013. Kinetic mechanism and inhibition of *Mycobacterium tuberculosis* d-alanine: D-alanine ligase by the antibiotic d-cycloserine. *FEBS J.* 280(4):1150–1166.
- Quémard, A., Lanéelle, G. & Lacave, C., 1992. Mycolic acid synthesis: a target for ethionamide in mycobacteria? *Antimicrob Agents Chemother.* 36(6):1316–1321.
- Ramachandran, G., Kupparam, H.K.A., Vedhachalam, C., Thiruvengadam, K., et al., 2017. Factors influencing tuberculosis treatment outcome in adult patients treated with thrice-weekly regimens in India. *Antimicrob Agents Chemother.* 61(5):1-12.



- Reviono, Kusnanto, P., Eko, V., Pakiding, H., Nurwidiansih, D., 2014. *Multidrug resistant tuberculosis* (MDR-TB): Tinjauan epidemiologi dan faktor risiko efek samping obat anti tuberkulosis. *MKB* 46(4):189-196.
- Ruddy, M., Balabanova, Y., Graham, C., Fedorin, I., et al., 2005. Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia. *Thorax* [Online] 60(2):130–135. Available from: doi:10.1136/thx.2004.026922.
- Ruesen, C., van Gageldonk-Lafeber, A.B., de Vries, G., Erkens, C.G., et al., 2014. Extent and origin of resistance to antituberculosis drugs in the Netherlands, 1993 to 2011. *Euro Surveill.* 19 (11):1-10.
- Samuels, J.P., Sood, A., Campbell, J.R., Khan, F.A., et al., 2018. Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis. *Sci Rep.* [Online] 8(1):4980. Available from: doi:10.1038/s41598-018-23344-z.
- Schaberg, T., Rebhan, K. & Lode, H., 1996. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. *Eur Respir J.* 9(10):2026–2030.
- Silva, A.D., Eduardo, P. & Palomino, J.C., 2011. Molecular basis and mechanisms of drug resistance in *Mycobacterium tuberculosis*: classical and new drugs. *J Antimicrob Chemother.* [Online] 66(7):1417–1430. Available from: doi:10.1093/jac/dkr173.
- Singla, R., Khan, N., Al-Sharif, N., Ai-Sayegh, M.O., et al., 2006. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. *Int J Tuberc Lung Dis.* 10 (1):74–79.
- Smith, T., Wolff, K.A. & Nguyen, L., 2013. Molecular Biology of Drug Resistance in *Mycobacterium tuberculosis*. *Curr Top Microbiol Immunol.* [Online] 374:53-80. Available from: doi:10.1007/82\_2012\_279.
- Soepandi, P., 2014. Hasil pengobatan dan variasi biaya TB-MDR/XDR dengan strategi PMDT di RSUP Persahabatan. *J ARSI* 1(1):19-25.
- Suchindran, S., Brouwer, E.S. & Rie, A.V., 2009. Is HIV Infection a Risk Factor for Multi-Drug Resistant Tuberculosis? A Systematic Review. *PLOS ONE* [Online] 4(5):1-9. Available from: doi:10.1371/journal.pone.0005561.
- Sudigdo Sastroasmoro & Sofyan Ismael (eds.) , 2014. *Dasar - Dasar Metodologi Penelitian Klinis*. 5th edition. Jakarta, Sagung Seto.



- Tang, S., Tan, S., Yao, L., Li, F., et al., 2013. Risk Factors for Poor Treatment Outcomes in Patients with MDR-TB and XDR-TB in China: Retrospective Multi-Center Investigation. *PLoS ONE* [Online] 8(12):1-8. Available from: doi:10.1371/journal.pone.0082943.
- Tamsil, T.A., Nawas, A., Sutoyo, D.K., 2014. Pengobatan multidrug resistant tuberculosis (MDR-TB) dengan panduan jangka pendek. *J Respir Indo* 34(2):109-121.
- Telenti, A., Imboden, P., Marchesi, F., Matter, L., et al., 1993. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. *Lancet* [Online] 341(8846):647-651. Available from: doi:10.1016/0140-6736(93)90417-F.
- van Altena, R., de Vries, G., Haar, C.H., de Lange, W.C.M., et al., 2015. Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000-2009. *Int J Tuberc Lung Dis.* [Online] 19(4):406-412. Available from: doi:10.5588/ijtld.14.0838.
- WHO, 2016. *Global tuberculosis report 2016*. World Health Organization, Geneva.
- WHO, 2016. Indonesia: Tuberculosis profile. [cited 2017 May 28]. Available from:  
[https://extranet.who.int/sree/Reports?op=Replet&name=%2FWHO\\_HQ\\_Reports%2FG2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=ID&LAN=EN&outtype=pdf](https://extranet.who.int/sree/Reports?op=Replet&name=%2FWHO_HQ_Reports%2FG2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=ID&LAN=EN&outtype=pdf)
- WHO, 2016. Tuberculosis: fact sheet. [cited 2017 May 28]. Available from:  
<http://www.who.int/mediacentre/factsheets/fs104/en/>
- WHO, 2011. The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis - reprinted with changes, 2011. Available at:  
[www.who.int/iris/bitstream/10665/44437/1/9789241500340\\_eng.pdf](http://www.who.int/iris/bitstream/10665/44437/1/9789241500340_eng.pdf).
- WHO, 2016. WHO treatment guidelines for drug-resistant tuberculosis: 2016 update. (Cited 2017 May 27). Available at:  
<http://www.who.int/tb/MDRTBguidelines2016.pdf>
- WHO, 2008. *WHO policy statement: molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis*. [Online] [cited 2017 June 8]. WHO. Available from:  
[http://www.who.int/tb/laboratory/line\\_probe\\_assays/en/](http://www.who.int/tb/laboratory/line_probe_assays/en/)
- Yew, W.W., Chan, C.K., Leung, C.C., Chau, C.H., et al., 2003. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant



tuberculosis. *Chest* [Online] 124(4):1476–1481. Available from:  
doi:10.1378/chest.124.4.1476

Yuan, B., Du, J., Lan, X, Zhou, M., Wang, J., Wang, W., 2017. Effect of type 2 diabetes mellitus on sputum negative conversion and treatment effects of multi-drug-resistant tuberculosis. *Biomed Res.* 28(9):3917-3922.

Zhang, C., Wang, Y., Shi, G., Han, W., et al., 2016. Determinants of multidrug-resistant tuberculosis in Henan province in China: a case control study. *BMC Public Health.* [Online] 16(42):1-8. Available from:  
doi:10.1186/s12889-016-2711-z.

Zhang, Y., Wu, S., Xia, Y., Wang, N., et al., 2017. Adverse events associated with treatment of multidrug-resistant tuberculosis in China: An ambispective cohort study. *Med Sci Monit.* 23:2348–2356.